Cost-effectiveness of different types of stents in the correction of chronic total occlusion

Aim. To study cost-effectiveness of different types of stents in the correction of chronic total occlusion (CTO).
Methods. The study included 119 patients after successful coronary artery CTO recanalization in 2009–2012. After 6.1±0.9 months and 12.7±1.6 months a control examination was performed (coronary angiography, intravascular ultrasound, optical coherence tomography). Negative events (in-stent restenosis and thrombosis) were analyzed. Taking into account the obtained data, direct costs were calculated including the cost of implants, and the cost of restenosis and thrombosis treatment.
Results. The highest frequency of in-stent restenosis (p < 0.05) was registered after IntrepideTM (in 57.1% cases) and Prolim® (in 47.4% cases) stent implantation while the similar events in cases of Taxus® Express 2, Xience V®/Xience Prime® LL, Endeavor® Resolute, Nobori® stent implantation were registered in 0–11.1% of cases. There weren’t differences in the thrombosis incidence between studied types of implants (p > 0.05). Based on the data obtained, the stents were classified as devices with low rate of adverse events (Taxus® Express 2, Xience V®/Xience Prime® LL, Endeavor® Resolute, Nobori® – LRAE group), and those with a high rate of restenosis and thrombosis (IntrepideTM and Prolim® – HRAE group).
The average cost of stents in the LRAE group was 2155.1 US dollars. Endovascular correction of in-stent restenosis were performed in 6.3% of cases, thrombosis – in 1.3%, the average direct treatment cost per patient over 12.7±1.6 months totaled 3906.4 US dollars.
In the HRAE group the cheaper devices were implanted (median cost was $1650.8). Repeated PCIs due to restenosis were performed in 52.5% of cases, one patient (2.5%) with verified thrombosis underwent CABG. The average direct treatment cost per patient over 12.7±1.6 months period was 4993.5 US dollars, which was $1,087.1 more than in the LRAE group.
Conclusion. The obtained data indicate higher financial cost during 12.7± 1.6 months follow-up period after IntrepideTM and Prolim® stent implantation in the recanalized CTO areas. This emphasizes the impotance of using coronary stents with proven minimal risks of in-trastent restenosis and thrombosis in CTO cases.

1. Di Mario C., Werner G.S., Sianos G., Galassi A.R., Büttner J., Dudek D., Chevalier B., Lefevre T., Schofer J., Koolen J., Sievert H., Reimers B., Fajadet J., Colombo A., Gershlick A., Serruys P.W., Reifart N. European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. EuroIntervention, 2007, vol. 3, no. 1, pp. 30-43.

2. Galassi A.R., Tomasello S.D., Reifart N., Werner G.S., Sianos G., Bonnier H., Sievert H., Ehladad S., Bufe A., Shofer J., Gershlick A., Hildick-Smith D., Escaned J., Erglis A., Sheiban I., Thuesen L., Serra A., Christiansen E., Buettner A., Costanzo L., Barrano G., Di Mario C. In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. EuroIntervention, 2011, vol. 7, no. 4, pp. 472-479. doi: 10.4244/EIJV7I4A77.

3. Stone G.W., Kandzari D.E., Mehran R., Colombo A., Schwartz R.S., Bailey S., Moussa I., Teirstein P.S., Dangas G., Baim D.S., Selmon M., Strauss B.H., Tamai H., Suzuki T., Mitsudo K., Katoh O., Cox D.A., Hoye A., Mintz G.S., Grube E., Cannon L.A., Reifart N.J., Reisman M., Abizaid A., Moses J.W., Leon M.B., Serruys P.W. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation, 2005, vol. 112, no. 15, pp. 2364-2372. doi: 10.1161/CIRCULATIONAHA.104.481283.

4. Waksman R., Saito S. Chronic total occlusions: a guide to recanalization. Chichester; Hoboken: Wiley-Blackwell, 2009. – 198 р.

5. Neumann F-J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A. P., Benedetto U., Byrne R. A., Collet J-P., Falk V., Head S. J., Jüni P., Kastrati A., Koller A., Kristensen S. D., Niebauer J., Richter D. J., Seferovic P. M., Sibbing D., Stefanini G. G., Windecker S., Yadav R., Zembala M. O . 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J, 2019, vol. 40, no. 2, pp. 87-165. doi: 10.1093/eurheartj/ehy394.

6. Werner G., Martin-Yuste V., Hildick-Smith D., Boudou N., Sianos G., Gelev V., Rumoroso J., Erglis A., Christiansen E., Escaned J., di Mario C., Hovasse T., Teruel L., Bufe A., Lauer B., Bogaerts K., Goicolea J., Spratt J., Gershlick A., Galassi A., Louvard Y. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J, 2018, vol. 39, no. 26, pp. 2484-2493. doi: 10.1093/eurheartj/ehy220.

7. Goel P.K., Khanna R., Pandey C.M., Ashfaq R. Long-term outcomes post chronic total occlusion intervention-implications of completeness of revascularization. J Interven Cardiol, 2018, vol. 31, no. 3, pp. 293-301. doi: 10.1111/joic.12480.

8. van Dongen I.M., Yilmaz D., Elias J., Claessen B., Delewi R., Knops R. E., Wilde A., van Erven L., Schalij M. J., Henriques J. Evaluation of the impact of a chronic total coronary occlusion on ventricular arrhythmias and long-term mortality in patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator (the eCTOpy-in-ICD Study). J Am Heart Assoc, 2018, vol. 7, pp. e008609. doi: 10.1161/JAHA.118.008609.

9. Patel V.G., Brayton K.M., Tamayo A., Mogabgab O., Michael T.T., Lo N., Alomar M., Shorrock D., Cipher D., Abdullah S., Banerjee S., Brilakis E.S. Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies. JACC Cardiovasc Interv, 2013, vol. 6, no. 2, pp. 128-136. doi: 10.1016/j.jcin.2012.10.011

10. Tanaka H., Tsuchikane E., Muramatsu T., Kishi K., Muto M., Oikawa Y., Kawasaki T., Hamazaki Y., Fujita T., Katoh O. A novel algorithm for treating chronic total coronary artery occlusion. J Am Coll Cardiol, 2019, vol. 74, no. 19, pp. 2392-2404. doi: 10.1016/j.jacc.2019.08.1049.

11. Nikolsky E., Gruberg L., Rosenblatt E., Grenadier E., Boulos M., Bernstein Z., Huber A., Gitman R., Bar-Deroma R., Markiewicz W., Beyar R. Chronic total occlusion due to diffuse in-stent restenosis: is brachytherapy the solution? Int J Cardiovasc Intervent, 2004, vol.6, no. 1, pp. 33-38.

12. Huang K.N., Grandi S.M., Filion K.B., Eisenberg M.J. Late and very late stent thrombosis in patients with second-generation drug-eluting stents. Can J Cardiol, 2013, vol. 29, no. 11, pp. 1488-1494. doi: 10.1016/j.cjca.2013.04.001.

13. Stelmashok V.I. Vnutristentovoe restenozirovanie v srednesrochnom periode posle uspeshno vy’polnennoy rekanalizacii hronicheskih okklyuziy koronarny’h arteriy antegradny’m dostupom [Intra-stent restenosis in the medium term after successful recanalization of chronic coronary artery occlusions with antegrade access]. Vesci NAN Belarusi Ser med navuk, 2019, vol. 16, no. 1, pp. 65-76. (in Russian).

14. Safley D., House J., Rutherford B., Marso S. Success rates of percutaneous coronary intervention of chronic total occlusions and long-term survival in patients with diabetes mellitus. Diabetes Vasc Dis Res, 2006, vol. 3, no. 1, pp. 45-51.

15. Werner G.S., Krack A., Schwarz G., Prochnau D., Betge S., Figulla H.R. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol, 2004, vol. 44, no. 12, pp. 2301-2306. doi: 10.1016/j.jacc.2004.09.040.

16. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.-A., Steg P.G., Morel M.-A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., Serruys P.W. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007, vol. 115, no. 17, pp. 2344-2351. doi: 10.1161/CIRCULATIONAHA.106.685313.

17. Koelbl C.O., Nedeljkovic Z.S., Jacobs A.K. Coronary chronic total occlusion (CTO): a review. Rev Cardiovasc Med, 2018, vol. 19, no. 1, pp. 33-39. doi: 10.31083/j.rcm.2018.01.896.

18. Hung C-S., Cheng C-L., Chao C-L., Kao H-L., Chen M-F., Lin N-P. Cost-effectiveness of drug-eluting stents in patients with stable coronary artery disease. J Formos Med Assoc, 2011, vol. 110, no. 2, pp. 109-14. doi: 10.1016/S0929-6646(11)60017-X.

19. Poder T.G., Erraji J., Coulibaly L.P., Koffi K. Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: systematic review and cost-benefit analysis. PLoS One, 2017, vol. 12, no. 5, p. e0177476. doi: 10.1371/journal.pone.0177476.

20. Pessoa J.A., Ferreira E., Araújo D.V., Maia E., da Silva F.S.M., de Oliveira M.S., de Albuquerque D.C. Cost-effectiveness of drug-eluting stents in percutaneous coronary intervention in Brazil’s Unified Public Health System (SUS). Arq Bras Cardiol, 2020, vol. 115, no. 1, pp. 80-89. doi: 10.36660/abc.20180292.